Irreversible alteration of extracellular vesicle and cell-free messenger RNA profiles in human plasma associated with blood processing and storage

Hyun Ji Kim1,2, Matthew J. Rames1,2, Samuel Tassi Yunga1,2, Randall Armstrong1, Mayu Morita4, Anh T. P. Ngo2, Owen J. T. McCarty2, Fehmi Civitci3, Terry K. Morgan1,2,4 & Thuy T. M. Ngo1,2,3*

The discovery and utility of clinically relevant circulating biomarkers depend on standardized methods that minimize preanalytical errors. Despite growing interest in studying extracellular vesicles (EVs) and cell-free messenger RNA (cf-mRNA) as potential biomarkers, how blood processing and freeze/thaw impacts the profiles of these analytes in plasma was not thoroughly understood. We utilized flow cytometric analysis to examine the effect of differential centrifugation and a freeze/thaw cycle on EV profiles. Utilizing flow cytometry postacquisition analysis software (FCMpass) to calibrate light scattering and fluorescence, we revealed how differential centrifugation and post-freeze/thaw processing removes and retains EV subpopulations. Additionally, cf-mRNA levels measured by RT-qPCR profiles from a panel of housekeeping, platelet, and tissue-specific genes were preferentially affected by differential centrifugation and post-freeze/thaw processing. Critically, freezing plasma containing residual platelets yielded irreversible ex vivo generation of EV subpopulations and cf-mRNA transcripts, which were not removable by additional processing after freeze/thaw. Our findings suggest the importance of minimizing confounding variation attributed to plasma processing and platelet contamination.

Circulating extracellular vesicles (EVs) and cell-free RNA (cfRNA) are promising biomarkers for early cancer detection1. EVs are a heterogeneous mixture of vesicles of varying size and composition that are released from cells2–5. Since EVs are either derived from the plasma membrane or the involvement of multivesicular endosome fusion with the cell surface, they have cell-specific antigens on their surface that may be antibody labelled for imaging and/or isolation in –omics analyses6–8. There is increasing evidence that EVs may transport a variety of proteins and nucleic acids, including being a potential carrier of cfRNA9,10. Cell-free messenger RNAs (cf-mRNA) specifically are protein coding mRNA molecules in plasma that may serve as biomarkers11,12. Since EVs may transport diverse extracellular RNAs, including cf-mRNA, there is an intense interest in the combination of these analytes for blood-based cancer diagnosis13,14.

Previous studies have suggested that ex vivo platelet activation and fragmentation affect EV profiles in serum and plasma15–21. Thus, the International Society of Extracellular Vesicles (ISEV) and International Society on Thrombosis and Haemostasis (ISTH) have recommended general platelet-poor plasma processing conditions for EV analysis22,23. However, how specific preanalytical variables can influence EV subpopulations was not thoroughly characterized. Others have shown that residual platelets also significantly affect plasma microRNA levels solely due to differences in blood processing methods16,17. However, no prior studies have specifically examined changes in cf-mRNA. Since common blood processing conditions for biobanking may not produce...
platelet-poor plasma\textsuperscript{16}, as guided by ISEV and ISTH, additional processing on banked samples after thawing may mitigate the effect of platelet activation on EVs and cf-mRNA analysis. However, which subpopulations of ex vivo generated EVs and cf-mRNA subtypes are removable or retained is unknown.

Despite the growing body of literature describing the impact of blood processing on EVs, standardization through light scatter calibration was not widely adopted in these studies to analyze EV subpopulations using flow cytometry. Flow cytometry has been increasingly utilized to characterize the heterogeneity of EV surface markers\textsuperscript{2,16,24–29}. Nonetheless, standardizing nanoscale flow cytometry for sub-micron sized EV detection can be challenging due to varying instrument settings and resolution\textsuperscript{26–28}. Recent efforts to ameliorate this have focused on Mie scattering theory modeling\textsuperscript{30–34}. An estimated relative size of an EV population can be derived from a given scatter intensity provided an assumed refractive index and specific optical configuration in a flow cytometer\textsuperscript{32–34}. Although quantifying the exact refractive index of EVs is challenging, previous measurements by either nanoparticle tracking analysis or fluorescence lifetime imaging microscopy suggested a potential range from 1.37 to 1.45 \textsuperscript{35–37}. Using National Institutes of Standards and Technology (NIST) traceable bead standards with known diameters and refractive indices, scatter-diameter curves can be generated via postacquisition analysis software\textsuperscript{30–34}. Given an effective refractive index of EVs, established scatter-diameter curves yielded reproducible EV measurement between instruments\textsuperscript{30–33}.

In this study, we systematically examined the variation of both EV and cf-mRNA subpopulations in human plasma due to blood processing and freeze thaw effect after \(\sim 80\) °C storage. EVs were analyzed by flow cytometry with standardization size and fluorescent calibration, and cf-mRNA levels were measured by multiplex RT-qPCR. We compared plasma derived from single spin (S1: 1000 \(\times g\) centrifugation for 10 min) and double spin (S2: 15,000 \(\times g\) secondary spin for 10 min after the initial single spin S1) analyzed freshly and after freezing. We examined how post-freeze/thaw processing removes and retains specific EV subpopulations as well as cf-mRNA originating from platelets, common cell types and tissue specific cells. Our analysis revealed subpopulations of EVs and cf-mRNA were irreversibly altered ex vivo in association with blood processing and freeze/thaw effects after storage.

Materials and methods

Blood sample collection and processing. All experimental protocols were reviewed and approved by the Oregon Health & Science University Institutional Review Board. All methods were carried out in accordance with relevant guidelines and regulations. Blood samples from healthy individuals were obtained from the Cancer Early Detection Advanced Research center (CEDAR) at Oregon Health and Science University. All samples were collected under institutional review board (IRB) approved protocols with informed consent from all participants for research use. Whole blood was collected from healthy individuals with 8.5 ml in ACD-A (BD Vacutainer, Becton Dickinson, cat. 364606), 10 ml in K2EDTA tubes (BD Vacutainer, Becton Dickinson, cat. 366463), 10 ml in heparin (BD Vacutainer, Becton Dickinson, cat. 367874), or 3 ml in sodium citrate tubes (BD Vacutainer, Becton Dickinson, cat. 369714) via antecubital vein puncture using a 21G butterfly needle (BD Vacutainer, Becton Dickinson, cat. 367281). Tubes were transported vertically at room temperature before processing. Within 1 h of blood withdrawal, 10 ml of whole blood was centrifuged at 1000 \(\times g\) for 10 min at room temperature with the highest acceleration and deceleration setting at ‘9’ using Eppendorf 5810-R centrifuge with S-4-104 Rotor. Plasma was collected until 10 min above the buffy coat and was labelled as S1. To obtain double spun plasma, S1 plasma was centrifuged in Eppendorf 5424R centrifuge at 15,000 \(\times g\) for 10 min at room temperature. The resulting supernatant of platelet-depleted plasma was collected and labelled as S2. S1 and S2 plasma samples did not undergo a freeze/thaw cycle. Plasma samples that were frozen at \(\sim 80\) °C and thawed at room temperature were labelled as S1FR and S2FR respectively. For post-thaw processing, S1FR was centrifuged in Eppendorf 5424R centrifuge at 15,000 \(\times g\) for 10 min at room temperature. The resulting supernatant was carefully transferred and designated as S1FRS2. All samples were collected and processed using a uniform protocol at Oregon Health and Science University. The overall schematic diagram of plasma processing steps was described in Supplementary Fig. S1.

Platelet counting using improved Neubauer haemocytometer. The platelet count was measured by the improved Neubauer haemocytometer (VWR Scientific Products, Piscataway, NJ) by two independent, experienced researchers. The total number of platelets were counted from the central 1 \(\times 1\) mm area consisting of 25 groups of 16 squares separated by closely ruled triple lines.

Flow cytometry set-up for light scatter and fluorescence calibration. Beckton-Dickinson FACSAria Fusion equipped with 488 nm (60 mW), 561 nm (100 mW), and 640 nm (100 mW) lasers was used. For optimal configuration of submicron size detection, 0.1 \(\mu m\) size filter was applied to the sheath fluidic system to reduce sheath fluid noise. The sample flow rate was set at 1, which was measured by mass discharge\textsuperscript{38} and determined to be 45 \(\mu l/min\). Timed collections were recorded for 60 s. Data collection was set using the SSC trigger threshold value of 200 using scatter wavelength at 488 nm. In order to calibrate light scattering, 152, 203, 303, 401, 510, and 600 nm polystyrene NIST-traceable beads (ThermoFisher Scientific, cat. 3150A, 3200A, 3300A, 3400A, 3500A, and 3600A) were serially diluted in 0.1 \(\mu m\) filtered D-PBS without calcium and magnesium (ThermoFisher Scientific, cat. 14190250). A minimum of 5000 events were recorded for 60 s. Particle diameter and scatter relationship was established utilizing FCMPass software (v3.09, http://nanopass.ccr.cancer.gov)\textsuperscript{35–38}. Median SSC-H intensity in arbitrary units was converted to standardized unit in EV diameter. To approximate EV diameter size, the average of effective refractive index (RI) data based upon published measurements were used. Detailed instructions for light scattering calibration based on a core–shell structure to model EVs were followed (Shell RI = 1.4800, Core RI: 1.3800, and shell thickness: 5 nm)\textsuperscript{32}. For fluorescence calibration, Quantum
Alexa Fluor 647 Molecule Equivalent Soluble Fluorochrome (MESF) (Bangs Laboratories, cat. 647), Quantum Alexa Fluor 488 MESF (Bangs Laboratories, cat. 488), or Quantum PE MESF (Bangs Laboratories, cat. 827) were used. Data collection was using the FSC trigger threshold value of 300 and analyzed using FSC-A vs SSC-A in arbitrary units. Utilizing FCMPass software, the fluorescent intensity in arbitrary units were converted to MESF standardized units. All measurements were analyzed using FlowJo software.

**Fluorescent antibody labeling of differentially processed plasma for flow cytometry.** To fluorescently label EV surface proteins, 5 µl of plasma was incubated with 5 µl of antibody mix prepared after established dilution series. CD9 Alexa Fluor 647 (R&D system, clone: #209306, cat. FAB1880R-100 µg) was diluted to a final concentration of 0.001 mg/ml for staining. CD63 Alexa Fluor 488 (ThermoFisher scientific, clone: MEM-259, cat. MA5-18149, concentration 0.26 mg/ml) was diluted to a final concentration of 0.0013 mg/ml for staining. CD41 PE (Biolegend, clone: HIPI8, cat. 303706) was diluted to a final concentration of 0.001 mg/ml for staining. For isotype controls, mouse IgG2B Alexa Fluor 647 conjugated isotype control (R&D system, cat. IC0014R), mouse IgG1 Alexa Fluor 488 conjugated isotype control (ThermoFisher Scientific, cat. MA518167), and mouse IgG1, k PE conjugated isotype control (Biolegend, cat. 981804) were used at the same concentration as matched stained controls and were recorded at the same dilution as stained and unstained samples. Incubation was done for 3 h at room temperature in the dark. The stained EV samples were further diluted 200-fold with 0.1 µm filtered DPBS without calcium and magnesium prior to acquiring the data using an abort rate of <5% and keeping the threshold rate below 20,000 events per second. To account for the electronic abort rate due to nanoparticle coincidence (also known as “swarming”), stained samples were serially diluted and validated via consistent median fluorescent intensity across plasma dilutions. A buffer-only control of 0.1 µm-filtered DPBS without calcium and magnesium was recorded at the same flow cytometer acquisition settings as all other samples, including triggering threshold, voltages, and flow rate. The buffer-only control had a count of <1000 events per second.

**Characterization of platelets using flow cytometry.** For counting platelets in differentially processed plasma, blood samples from three healthy individuals were obtained in 10 ml K2EDTA tubes (BD Vacutainer, Becton Dickinson, catalog number: 36643). Plasma was processed using single spin at 1000 x g (S1). To obtain double spin plasma, S1 plasma was centrifuged in Eppendorf 5424R centrifuge at 15,000 x g for 10 min at room temperature (S2). To investigate the CD9, CD63, and CD41 expression, 5 µl of S1 and S2 plasma was incubated with 5 µl of antibody mix prepared after established dilution series. CD9 Alexa Fluor 647 (R&D system, clone: #209306, cat. FAB1880R-100 µg) was diluted to a final concentration of 0.001 mg/ml for staining. CD63 Alexa Fluor 488 (ThermoFisher scientific, clone: MEM-259, cat. MA5-18149, concentration 0.26 mg/ml) was diluted to a final concentration of 0.0013 mg/ml for staining. CD41 PE (Biolegend, clone: HIPI8, cat. 303706) was diluted to a final concentration of 0.001 mg/ml for staining. For isotype controls, mouse IgG2B Alexa Fluor 647 conjugated isotype control (R&D system, cat. IC0014R), mouse IgG1 Alexa Fluor 488 conjugated isotype control (ThermoFisher Scientific, cat. MA518167), and mouse IgG1, k PE conjugated isotype control (Biolegend, cat. 981804) were used at the same concentration as matched stained controls and were recorded at the same dilution as stained and unstained samples. Incubation was done for 3 h at room temperature in the dark. The stained EV samples were further diluted 200-fold with 0.1 µm filtered DPBS without calcium and magnesium prior to acquiring the data using an abort rate of <5% and keeping the threshold rate below 20,000 events per second. To account for the electronic abort rate due to nanoparticle coincidence (also known as “swarming”), stained samples were serially diluted and validated via consistent median fluorescent intensity across plasma dilutions. A buffer-only control of 0.1 µm-filtered DPBS without calcium and magnesium was recorded at the same flow cytometer acquisition settings as all other samples, including triggering threshold, voltages, and flow rate. The buffer-only control had a count of <1000 events per second.

**RT-qPCR profiling of cell free mRNA.** For characterizing the effect of freeze thaw on cell free mRNA expressions, RNA was extracted using plasma processed with S1, S2, S1FR, S2FR, and S1FRS2 conditions. Cell free mRNA was isolated by using plasma/serum circulating and exosomal RNA purification Kit (Norgen Biotek, cat. 42800) followed by 10X Baseline-ZERO DNase treatment (Epigenetic, cat. DB0715K). DNase treated RNA samples were purified and further concentrated using RNA clean and concentrator (Zymo Research, cat. R1014). The purified RNA samples were assayed by RT-qPCR using custom selected 16 primers targeting MTND2, PPBP, B2M, PF4, ACTB, CORO1C, GSE1, GAPDH, SMC4, HBG1, NUSAP1, MIKI67, FGB, APOE, FGG, and ALB. Template RNA was mixed with Superscript III One-step RT-PCR system with Platinum Taq DNA polymerase (Invitrogen, cat. 11-732-020) to generate cDNA according to the protocol. PCR amplification products were treated with Exonuclease I (New England Biolabs, cat. M0293L) to digest single stranded primers at 37 °C for 10 min followed by inactivation of enzymes at 80 °C for 15 min. For RT-qPCR, cDNA from preamplification was diluted 1:80 and set-up in 96-well plates with SsoFast EvaGreen supermix with low ROX (BioRad, cat. 42800) followed by 10X Baseline-ZERO DNase treatment (Epicentre, cat. DB0715K). DNase treated RNA samples were purified and further concentrated using RNA clean and concentrator (Zymo Research, cat. R1014). The purified RNA samples were assayed by RT-qPCR using custom selected 16 primers targeting MTND2, PPBP, B2M, PF4, ACTB, CORO1C, GSE1, GAPDH, SMC4, HBG1, NUSAP1, MIKI67, FGB, APOE, FGG, and ALB. Template RNA was mixed with Superscript III One-step RT-PCR system with Platinum Taq DNA polymerase (Invitrogen, cat. 11-732-020) to generate cDNA according to the protocol. PCR amplification products were treated with Exonuclease I (New England Biolabs, cat. M0293L) to digest single stranded primers at 37 °C for 30 min followed by inactivation of enzymes at 80 °C for 15 min. For RT-qPCR, cDNA from preamplification was diluted 1:80 and set-up in 96-well plates with SsoFast EvaGreen supernix with low ROX (BioRad, cat. 1725211) with above primers at 10 µM. QuantStudio 7 Flex (Applied Biosystems) was used to run RT-qPCR assay according to manufacturer’s recommended cycling conditions.

**Statistical analysis.** Significance for platelet count measurements using the improved Neubauer haemocytometer and flow cytometry across differential centrifugation were both assessed using the Wilcoxon test. To determine the impact of overall preanalytical factors, statistical analysis was performed on CD9+, CD63+, or CD41+ EVs on specific gated populations across differential centrifugation and freeze/thaw processing. The significance of individual preanalytical factor comparisons were determined using Tukey’s multiple comparison test. P values < 0.05 were considered statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001). Analyses were conducted using R package.
Results

Light scattering and fluorescence calibration. We calibrated the flow cytometer Beckton-Dickinson FACSAria Fusion using National Institutes of Standards and Technology (NIST) traceable size standard beads (152, 203, 303, 401, 510, and 600 nm) and Quantum Molecules of Equivalent Soluble Fluorophore (MESF) to establish standardized units for light scatter and fluorescence respectively. For light scatter, each bead sample was analyzed at the same acquisition setting until >5000 bead events were recorded. The histogram of each sized bead population revealed distinct side scattering in arbitrary units, where a progressive increase in SSC-H with increasing NIST bead diameter (152–600 nm) was observed (Fig. 1A). The median light scatter statistic of each bead size gated population was inputted into flow cytometry postacquisition analysis software (FCMpass) to calibrate light scattering. The collection half-angle of our system, which is important to quantify the amount of light reaching a detector in absolute units, was determined to be 45.3° using FCMpass software. Utilizing the side scattering collection angle, recorded side scattering value in arbitrary units was standardized to predicted scattering cross-section using Mie theory. The linear regression between our observed light scattering power in arbitrary units and predicted scattering cross-section resulted in $R^2 = 0.9991$ (Fig. 1B). The acquired scattering intensity of standard beads (red dots) was plotted on modelled data (black line) for polystyrene beads, which revealed the model fitted actual data accurately (Fig. 1C). After scatter-diameter relationship for EVs is extrapolated using FCMpass software, the measured scatter signal for polystyrene beads corresponding to vesicle diameter is revealed (Fig. 1C). Approximate diameters of EVs was calculated using the average of effective EV refractive index (Shell RI = 1.4800, Core RI: 1.38000, and shell thickness: 5 nm) Next, we performed fluorescence calibration using forward scatter as the trigger threshold to gate micron-sized MESF beads. MESF beads for each fluorophore was analyzed until >5000 bead events were recorded. While FSC-A vs. SSC-A revealed a single microsphere population, four fluorescent microspheres were observed with varying fluorescence intensity in arbitrary units (Fig. 2A, B). The median fluorescence statistic of each bead fluorescence gated population was inputted into flow cytometry postacquisition analysis software (FCMpass) to calibrate fluorescence (Fig. 2C). The relationship between MESF bead reference values and acquired fluorescence in arbitrary units was established to calibrate fluorescence (Fig. 2D).

Flow cytometry reveals distinct vesicle populations differentially affected by blood processing condition. After establishing light scatter and fluorescence calibration, we investigated the impact of differential centrifugation on plasma EVs using the flow cytometer. Whole blood was collected in EDTA, and plasma was differentially processed using single centrifugation at 1000 × g for 10 min (S1) and double centrifugation (S2: 15,000 × g secondary spin for 10 min after the initial single spin S1) (Fig. 3A, Supplementary Fig. S1). Complete removal of red blood cells from plasma S1 contained an average platelet concentration of 313 ± 74 thousand/µl while secondary spin resulted in the removal of more than 99.99% of residual platelets in S2 (Fig. 3B). Using flow cytometer, single spun plasma S1 contained an average platelet concentration of 15,000 × g while secondary spin resulted in removal of more than 99.99% of residual platelets in S2, consistent with the reduction measured by the haemocytometer (Supplementary Fig. S2A). For EV analysis, plasma was stained with anti-CD9, anti-CD63, and anti-CD41 fluorescent antibodies and measured by flow cytometry. The fluorescently positive gated data revealed that there are distinct populations in EV diameter distribution ranging between 150 and 3000 nm (Fig. 3C). It is noted that the subset of EVs within 150–1000 nm range at around 500 nm is an artifact of Mie scattering calibration from our calculated flow cytometer collection angle and geometry. Specifically, this corresponds to a plateau in the scatter-diameter curve from ~400–480 nm using predicted EV light scattering from the estimated average EV refractive index employed in our model (Fig. 1C). Welsh et al. reported a similar observation, suggesting that a plateau from the scatter-diameter curve resulted in an artifact between 400 and 480 nm accordingly. Therefore, we gated EVs into two populations: 150–1000 nm which may be comprised of small and medium EVs, and 1000–3000 nm comprised of large EVs and platelets. Notably, we observed much less 150–1000 nm CD41+ EVs for both S1 and S2 compared to 150–1000 nm CD9+ and CD63+ EVs. Flow cytometer assay controls included unstained samples, isotype controls, serial dilution of stained plasma, and antibody with buffer alone (Supplementary Fig. S3). Serial dilution of stained plasma showed the linear detection of EVs while the median fluorescence intensity remained constant, suggesting that EVs were detected and counted as single particles via flow cytometry. Plasma condition at S2 resulted in a clear reduction in 1000–3000 nm populations compared to S1 while the 150–1000 nm EVs remained similar for plasma from both processing conditions (Fig. 3C).

Freezing of platelet containing single spun plasma generates ex vivo EVs. Previous studies have suggested that ex vivo platelet activation and fragmentation generate EVs. We tested CD9, CD63, and CD41 expression on platelets and observed platelets expressed CD9, CD63, and CD41 (Supplementary Fig. S2B and C). Therefore, we examined how the freeze/thaw effect on plasma containing residual platelets impacts EV profiles using anti-CD9, anti-CD63, and anti-CD41 fluorescent antibodies. We compared EVs measured freshly (S1 and S2) with EVs after a freeze/thaw cycle (S1FR and S2FR) (Fig. 4A, Supplementary Fig. S4). The 1000–3000 nm CD9+ EV concentration in S1 plasma sample was around 11,103/µl while the 150–1000 nm CD9+ EV concentration in S1 plasma sample was around 9610/µl (Fig. 4B). We observed remarkably increased CD9+ EVs for both 1000–3000 nm and 150–1000 nm populations after single freeze/thaw cycle of S1 plasma (S1FR vs. S1, P < 0.001). On average, we observed a threefold increase for 1000–3000 nm CD9+ EVs and a 5.5-fold increase for 150–1000 nm CD9+ EVs between S1FR and S1. The 1000–3000 nm CD9+ EV concentration in S2 plasma sample was around 381/µl while the 150–1000 nm CD9+ EV concentration in S2 plasma sample was more comparable to
S1 at around 12,976/µl (Fig. 4B). However, we observed no significant changes in CD9⁰ EVs occurred after single freeze/thaw cycle of S2 plasma samples for either size (S2FR vs. S2, ns). Similarly, the 1000–3000 nm CD63⁺ EVs were significantly increased in single spun plasma after freeze/thaw (S1FR vs. S1, P < 0.01) while remaining the same for double spun plasma (S2FR vs. S2, ns) (Fig. 4B). The concentration of CD63⁺ EVs in S1 plasma was around 6997/µl and 12,493/µl for 1000–3000 nm and 150–1000 nm respectively. On average, we observed a 2.4-fold increase for 1000–3000 nm CD63⁺ EVs between S1FR and S1. In contrast, the
150–1000 nm CD63+ EVs were statistically unchanged with respect to either spin freeze/thaw cycle (Fig. 4B). When looking at the changes for CD41+ EVs, the 150–1000 nm populations increased remarkably after a single freeze/thaw cycle of S1 plasma (S1FR vs. S1, \( P < 0.0001 \)) (Fig. 4B). The 1000–3000 nm CD41+ EV concentration in S1 plasma sample was around 7847/µl while the 150–1000 nm CD41+ EV concentration in S1 plasma sample was around 2365/µl. For single spun plasma, while 1000–3000 nm CD41+ EVs showed no significant change (S1FR vs. S1, ns), we observed a 16.3-fold increase for 150–1000 nm CD41+ EVs between S1FR and S1. The 1000–3000 nm CD41+ EV concentration in S2 plasma sample was around 77/µl while the 150–1000 nm CD41+ EV concentration in S2 plasma sample was around 933/µl (Fig. 4B). Overall, a single freeze/thaw cycle on double spun plasma resulted in no significant change for CD9+, CD63+, and CD41+ EVs for either size ranges (S2FR vs S2, ns). To confirm the nature of EVs which are sensitive to detergent lysis, we applied detergent to disrupt EVs found in S1FR and S2FR. We found a disappearance of CD9+, CD63+, and CD41+ stained EVs through detergent treatment, validating the detected difference is not due to false-positive events derived from antibody aggregates (Supplementary Fig. S4).

In addition, we have also tested the effect of four different types of anticoagulant tubes (ACD, EDTA, heparin, and sodium citrate) in association with freeze/thaw cycle on differentially processed plasma (Supplementary Fig. S5). We observed the least change for 1000–3000 nm CD9+ and CD41+ EVs between S1 and S1FR in sodium citrate, while the lowest for 1000–3000 nm CD63+ EVs was from ACD. Overall, we observed a more than twofold increase for 150–1000 nm CD9+ and CD41+ EVs between S1 and S1FR in all anticoagulant tube types (Supplementary Fig. S5). In contrast, we observed no increase for 150–1000 nm CD63+ EVs between S1 and S1FR for any anticoagulant tube type. Throughout all anticoagulant tube types, minimal changes occurred between S2 and S2FR for CD9+, CD63+, and CD41+ EVs in both 150–1000 nm and 1000–3000 nm EV size ranges. In summary, our data indicated that freezing single spun plasma which contains residual platelets generated ex vivo EVs in a marker dependent manner, whereas no significant change was observed for residual platelet depleted plasma in the second spin prior to freezing.
Ex vivo generated EVs are irreversible even after post-thaw processing. Next, to test if a post-thaw processing effectively removes ex vivo generated EVs, we performed centrifugation at 15,000 g for 10 min on S1FR plasma samples (S1FRS2) (Fig. 5A). We found S1FRS2 significantly depleted CD9+, CD63+, and CD41+ 1000–3000 nm populations associated with S1FR (Fig. 5B, C). The concentrations of 1000–3000 nm CD9+ EVs, CD63+ EVs, and CD41+ EVs in S1FR plasma sample were around 34,259/µl, 16,727/µl, and 11,279/µl respectively, while the concentrations of 150–1000 nm CD9+ EVs, CD63+ EVs, and CD41+ EVs in S1FR plasma sample were around 52,873/µl, 13,090/µl, and 38,588/µl respectively. When comparing between S1FR and S1FRS2, we observed 8.8-fold, 11.5-fold, and 3.9-fold decreases in 1000–3000 nm CD9+, CD63+, and CD41+ EVs respectively (Fig. 5C). Notably, these CD9+, CD63+, and CD41+ 1000–3000 nm levels in S1FRS2 were not significantly different compared to S2FR (S1FRS2 vs S2FR, ns) (Fig. 5C). Meanwhile, the levels of small and medium CD9+ and CD41+ EVs associated with S1FR remained significantly higher in post-thaw processed plasma S1FRS2 compared to S2FR (S1FRS2 vs S2FR, P< 0.05 for EV diameter 150–1000 nm) (Fig. 5B, C). On average, we observed 4.8-fold and 27.4-fold differences between S2FR and S1FRS2 in 150–1000 nm CD9+ and CD41+ EVs respectively. In contrast, we observed 150–1000 nm CD63+ EVs remained statistically unchanged (S1FRS2 vs S2FR, ns) (Fig. 5B, C). These CD9+, CD63+, and CD41+ 150–1000 nm levels in S1FRS2 were not significantly different compared to S1FR (S1FRS2 vs S1FR, ns). Collectively, our results revealed freezing residual platelets in S1 significantly generated small and medium CD9+ and CD41+ EVs ex vivo, which post-thaw processing could not remove. Meanwhile, we observed CD63+ EVs were retained regardless of spinning and post-thaw processing conditions.

Distinct subsets of cf-mRNA influenced by differential centrifugation and post-thaw processing. Since platelets and EVs contain mRNA, we sought to determine if blood centrifugation and post-thaw processing affected cf-mRNA levels. We analyzed cf-mRNA profiles in single and second spin plasma freshly (S1 and S2), after freezing at ~ 80 °C (S1FR and S2FR), and for samples subjected to a second spin following S1FR processing (S1FRS2). We selected a panel of housekeeping, platelet and tissue-specific genes for multiplex RT-qPCR measurements (Fig. 6A, B). Hierarchical clustering analysis of relative gene expression between post-thaw processed samples revealed three distinct clusters (Fig. 6A). Overall, these clusters were either dependent (non-tissue specific) or independent (tissue specific) of post-thaw processing conditions, wherein non-tissue specific genes segregated into two clusters. The first cluster included genes (HBG1 and SMC4 for example), which could be removed by post-thaw processing and therefore were likely related to large EVs or platelets (Fig. 6A, B). The second cluster, including platelet genes and house-keeping genes such as PF4 and B2M, was partially removed by post-thaw processing and therefore was likely associated with ex vivo generated small and medium EVs which
remained after post-thaw processing (Fig. 6A, B). Importantly, our results revealed that tissue specific gene signatures (such as genes expressed in liver tissue; including APOE and ALB) were retained regardless of spinning and post-thaw processing conditions (Fig. 6A, B), suggesting they are present in non-platelet small or medium EVs. The relationship of cf-mRNA transcripts with EV subpopulations requires further investigation and is the subject of future studies. Overall, as genes from different biological roles are uniquely affected by preanalytical differences, the selection of novel cfRNA biomarkers should consider the effects of preanalytical variability.

Discussion
Circulating EVs and cf-RNA are promising biomarkers for disease diagnosis and prognosis41–44. However, significant variability in standardizing blood processing across published methods has led to a lack of reproducibility between studies2,16,17,45. In this study, we utilized multiparametric flow cytometry and cf-mRNA profiling to characterize preanalytical influences on EV and cf-mRNA subpopulations in plasma. We observed two distinct subpopulations by flow cytometry which are differentially impacted by centrifugation and post-thaw processing. Interestingly, we observed small and medium CD9+ EVs and CD41+ EVs were irreversibly generated via freezing single spun plasma while CD63+ EVs remained similar. Importantly, these ex vivo generated EVs could not be removed by additional centrifugation after freeze/thaw, and thereby can significantly affect downstream analyses. As a first in cf-mRNA studies, we also found groups of genes significantly, partially, or unaffected by post-thaw processing in plasma.

Since different types of EV purification methods (ultracentrifugation, density gradients, size-filtration, etc.) affect the yield and purity of EVs46,47, we chose to fluorescently label EVs directly in plasma using EV tetraspanin-specific antibodies with proper assay controls according to recent MIFlowCyt-EV reporting framework48. Previous study highlighted effects of centrifugation on pre-isolated EVs from platelets and erythrocytes by examining recovery of EVs through differential centrifugation49. However, their freeze–thaw cycle was performed on purified EVs, leading to no significant change across different temperatures of single freeze–thaw cycle. By examining EVs directly in plasma, we observed irreversible ex vivo generation of EVs and cf-mRNA subpopulations altered by differential centrifugation and post-thaw processing.

The choice of anticoagulant used during blood collection is another important preanalytical factor which influences downstream analyses and the extent of ex vivo release25,30,31. Other studies also have tested different anticoagulant tubes focusing on platelet microparticles or large EVs50,51. György et al. showed the highest CD42a+Annexin V+ platelet microparticle counts using flow cytometry were found in heparin compared to citrate
and ACD tubes. Lacroix et al., also examined Annexin V+ platelet microparticles using flow cytometry and
found the most Annexin V+ platelet microparticles in decreasing order for EDTA, heparin, and citrate tubes.39. After establishing light scattering calibration using flow cytometry, we have found the impact of anticoagulant
tubes differed based on the markers being tested (CD9, CD63, or CD41) and size ranges (150–1000 nm EVs vs
1000–3000 nm EVs). Our study revealed that the combined effect of both freezing and anticoagulation with
the highest fold change in 1000–3000 nm CD41+ EVs was found in heparin compared to EDTA, ACD, and
sodium citrate tubes. However, EDTA generated the highest fold change in 1000–3000 nm CD9+ and CD63+
EVs. For 150–1000 nm EVs, EDTA generated the highest fold change for CD9+ and CD41+ EVs while the rela-
tive levels of CD63+ EVs were similar across all anticoagulants. Similar to Jayachandran et al. and Lacroix et al.,
we also found that counts of 1000–3000 nm large EVs were similar both before and after freezing single spun
plasma. Although we found the relative effect of anticoagulant types can be minimized by freezing samples as
secondary spun plasma, it is important to test and choose anticoagulant types to fit specific research questions
and downstream analysis.

Although previous studies highlighted the preanalytical influences on microparticle generation associated
with platelet activations40,49,55, the effect of blood processing on EV subpopulations using flow cytometry with
light scattering and fluorescence standardized calibration is lacking. The enumeration of microparticles in pre-
vious studies mostly utilized flow cytometry that was validated to discriminate between 0.5 and 0.9 μm Megamix beads.15,16. Since considerable efforts have been directed to establish a standardized methodology for EV measure-
ments by flow cytometry30–33, we applied this standardized approach to investigate enumeration of EVs influenced
by preanalytical factors. Utilizing the FCMpass software developed by Welsh et al.32–34, we observed differential
centrifugation results in distinct EV subpopulations within the diameter range between 150 and 3000 nm. In
addition, our freeze thaw analysis further revealed ex vivo generated CD9+ EVs, adding to the body of literature
on platelet-associated blood processing artefacts.5,16. We addressed the importance of preanalytical influences on
EVs using a standardized approach, which will improve the reproducibility with respect to effective EV diameter
and given fluorochrome molecule standards across literatures.

Figure 5. Effect of post-thaw processing on EVs using flow cytometry. (A) Schematic diagram of differentially
processed plasma (S1, S2), respective freeze thaw samples (S1FR, S2FR), and secondary spin after post-freeze/
thaw plasma S1FR (S1FRS2). (B) Representative flow cytometry dot plot of EV diameter (nm) versus fluorescent
intensity in Quantum MESF units for CD9+ EVs, CD63+, and CD41+ EVs in S1FR, S2FR, and S1FRS2 conditions using FlowJo. Quantum Alexa Fluor 647 MESF is used for Alexa Fluor 647 conjugated CD9 stained plasma, Quantum Alexa Fluor 488 MESF is used for Alexa Fluor 488 conjugated CD63 stained plasma, and Quantum PE MESF is used for PE conjugated CD41 stained plasma. Events were gated from 150 to 1000 nm (green box) and from 1000 to 3000 nm (red box). (C) Box plot of CD9+, CD63+, and CD41+ EV concentration from 1000–3000 nm (red) and 150–1000 nm (green) for S1FR, S2FR, and S1FRS2 using R. Statistical significance were obtained from three healthy volunteers for each freeze thaw processing condition using Tukey’s multiple comparisons (ns = not significant, P > 0.05; *P < 0.05, ***P < 0.001, ****P < 0.0001).
Comprehensive assessment of light scattering sensitivity on multiple different flow cytometers was performed by Van der pol et al.\(^{30}\). For small particle detection, only a few flow cytometers detected more than three different sized reference beads using both side scatter (SSC) and forward scatter (FSC). Similarly, our instrument could not detect more than three sized reference beads by FSC. Instead, we utilized FCMpass software to calibrate SSC using the effective refractive index of EVs (Shell RI = 1.4800, Core RI: 1.3800, and shell thickness: 5 nm)\(^{32}\). Since the true refractive index of different EV subpopulations is currently unknown, the average EV refractive indices based on core–shell theory has been implemented\(^{32,33}\). Although EVs in the ~1000 nm diameter range may overlap with small platelets\(^{56}\), precise refractive indices which considers platelet granularity and shapes is currently unknown. Specific studies, which definitively parse EVs from small platelets and understanding refractive indices of EV subpopulations, are needed to better define EV physical characteristics and compositions.

How blood processing influences circulating microRNA has been previously shown\(^{16,17}\), and yet the impact on cf-mRNA is poorly understood. Cheng et al. provided preanalytical influences on miRNA expression due to differing residual platelet amount\(^{17}\). Conversely, our study investigated the impact of blood processing conditions through differential centrifugation, respective freezing condition, and post-thaw processing on cf-mRNA. We revealed cf-mRNA groups whose extent of preanalytical variability differed based on the degree of residual platelets in plasma. In particular, non-tissue specific genes were further classified as either partially or fully removed by post-freeze/thaw processing. Intriguingly, tissue-specific cf-mRNA were less prone to blood processing conditions, revealing them as potentially more robust biomarkers, or differentially associated with smaller vesicle subpopulations retained through centrifugation.

In conclusion, our study provides an assessment of the preanalytical effect of differential centrifugation and freeze/thaw cycles on plasma EVs and cf-mRNA. Employing multiparametric flow cytometry, our work provides insights into how preanalytical factors influence EV subpopulations and ex vivo release of EVs in association with residual platelets. Notably, these artifacts appear to be irreversible for CD9\(^+\) and CD41\(^+\) small and medium EVs and mRNA transcripts of genes present in platelets. However, an increasing number of other marker-specific studies, including non-platelet specific markers, will help to address the origin of the ex vivo EV generation observed in our study. Our results indicate distinct subpopulations of EVs and cf-mRNA are not removable by additional spinning after freeze/thaw. Therefore, consideration should be taken when analyzing EVs and cf-mRNA from banked plasma and designing robust EV and cf-mRNA based liquid biopsy tests.

Received: 21 December 2020; Accepted: 19 January 2022
Published online: 08 February 2022

References

1. Müller, J. B. et al. Circulating biomarkers in patients with glioblastoma. Br. J. Cancer \textbf{122}, 295–305 (2019).
2. Marcoux, G. et al. Revealing the diversity of extracellular vesicles using high-dimensional flow cytometry analyses. Sci. Rep. 6(1), 35928 (2016).
3. Maas, S. L. N., Breakfield, X. O. & Weaver, A. M. Extracellular vesicles: Unique intercellular delivery vehicles. Trends Cell Biol. 27(3), 172–188 (2017).
4. Willms, E. et al. Extracellular vesicle heterogeneity: Subpopulations, isolation techniques, and diverse functions in cancer progression. Front. Immunol. 9, 738–738 (2018).
5. Raposo, G. & Stoorvogel, W. Extracellular vesicles: Exosomes, microvesicles, and friends. J. Cell Biol. 200(4), 373–383 (2013).
6. Kalluri, R. The biology and function of exosomes in cancer. J. Clin. Investig. 126(4), 1208–1215 (2016).
7. McAndrews, K. M. & Kalluri, R. Mechanisms associated with biogenesis of exosomes in cancer. Mol. Cancer 18(1), 52–52 (2019).
8. György, B. et al. Membrane vesicles, current state-of-the-art: Emerging role of extracellular vesicles. Cell. Mol. Life Sci. 68(16), 2667–2688 (2011).
9. Murillo, O. D. et al. ExRNA atlas analysis reveals distinct extracellular RNA cargo types and their carriers present across human biofluids. Cell 177(2), 463–477 (2019).
10. Hinger, S. A. et al. Diverse long RNAs are differentially sorted into extracellular vesicles secreted by colorectal cancer cells. Cell Rep. 25(3), 715–725 (2018).
11. Pós, O. et al. Circulating cell-free nucleic acids: Characteristics and applications. Eur. J. Hum. Genet. 26(7), 937–945 (2018).
12. Kishikawa, T. et al. Circulating RNAs as new biomarkers for detecting pancreatic cancer. World J. Gastroenterol. 21(28), 8527–8540 (2015).
13. Ngo, T. T. et al. Noninvasive blood tests for fetal development predict gestational age and preterm delivery. Science 360(6393), 1133–1136 (2018).
14. Lin, J. et al. Exosomes: Novel biomarkers for clinical diagnosis. Sci. World J. 2015, 1–9 (2015).
15. Wüthner, K. W. et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J. Extracell. Vesicles 2(1), 20360 (2013).
16. Mitchell, A. J. et al. Platelets confound the measurement of extracellular miRNA in archived plasma. Sci. Rep. 6, 32651–32651 (2016).
17. Cheng, H. H. et al. Plasma processing conditions substantially influence circulating microRNA biomarker levels. PLoS ONE 8(6), e64795–e64795 (2013).
18. Menck, K. et al. Isolation and characterization of microvesicles from peripheral blood. J. Vis. Exp. 119, 55057 (2017).
19. Brisson, A. R. et al. Extracellular vesicles from activated platelets: A semiquantitative cryo-electron microscopy and immuno-gold labeling study. Platelets 28(3), 263–271 (2017).
20. Menck, K. et al. Characterisation of tumour-derived microvesicles in cancer patients’ blood and correlation with clinical outcome. J. Extracell. Vesicles 6(1), 1340745 (2017).
21. Autonen, M. T. et al. Isolation and characterization of platelet-derived extracellular vesicles. J. Extracell. Vesicles 3, 24692. https://doi.org/10.3402/jev.v3.24692 (2014).
22. Théry, C. et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018); A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 7(1), 1535790 (2018).
23. Lacroix, R. et al. Standardization of pre-analytical variables in plasma microparticle determination: Results of the International Society on Thrombosis and Haemostasis S&G Collaborative workshop. J. Thromb. Haemost. https://doi.org/10.1111/jth.12207 (2013).
24. Hargett, L. A. & Bauer, N. N. On the origin of microparticles: From “platelet dust” to mediators of intercellular communication. Palm. Curr. 3(2), 329–340 (2015).
25. Morgan, T. K. Cell- and size-specific analysis of placental extracellular vesicles in maternal plasma and pre-eclampsia. Transl. Res. 201, 40–48 (2018).
26. Robert, S. et al. Standardization of platelet-derived microparticle counting using calibrated beads and a Cytometrics FC500 routine flow cytometer: A first step towards multicenter studies?. J. Thromb. Haemost. 7(1), 190–197 (2009).
27. Poncelet, P. et al. Standardized counting of circulating platelet microparticles using currently available flow cytometers and scatter-based triggering: Forward or side scatter?. Cytometry A 89(2), 148–158 (2016).
28. Jayachandran, M. et al. Methodology for isolation, identification and characterization of microvesicles in peripheral blood. J. Immunol. Methods 375(1–2), 207–214 (2012).
29. Van Der Vlist, E. J. et al. Fluorescent labeling of nano-sized vesicles released by cells and subsequent quantitative and qualitative analysis by high-resolution flow cytometry. Nat. Protoc. 7(7), 1311–1326 (2012).
30. van der Pol, E. et al. Standardization of extracellular vesicle measurements by flow cytometry through vesicle diameter approximation. J. Thromb. Haemost. 16(6), 1236–1245 (2018).
31. Van Der Pol, E. et al. Single vs. swarm detection of microparticles and exosomes by flow cytometry. J. Thromb. Haemost. 10(5), 919–930 (2012).
32. Welsh, J. A. et al. FCMPASS software aids extracellular vesicle light scatter standardization. Cytometry A 97(6), 569–581 (2020).
33. Welsh, J. A. & Jones, I. C. Small particle fluorescence and light scatter calibration using FCMPASS software. Curr. Protec. Cytom. 94(1), e79 (2020).
34. Welsh, J. A., Jones, I. C. & Tang, V. A. Fluorescence and light scatter calibration allow comparisons of small particle data in standard units across different flow cytometry platforms and detector settings. Cytometry A 97(6), 592–601 (2020).
35. van der Pol, E. et al. Refractive index determination of nanoparticles in suspension using nanoparticle tracking analysis. Nano Lett. 14(11), 6195–6201 (2014).
36. Gardiner, C. et al. Measurement of refractive index by nanoparticle tracking analysis reveals heterogeneity in extracellular vesicles. J. Extracell. Vesicles 3, 25361 (2014).
37. van Manen, H.-J. et al. Refractive index sensing of green fluorescent proteins in living cells using fluorescence lifetime imaging microscopy. Biophys. J. 94(8), L67–L69 (2008).
38. Noulser, E. et al. Differences in levels of platelet-derived microparticles in platelet components prepared using the platelet rich plasma, buffy coat, and apheresis procedures. Transfus. Apheres. Sci. 56(2), 135–140 (2017).
39. Lacroix, R. et al. Impact of pre-analytical parameters on the measurement of circulating microparticles: Towards standardization of protocol. J. Thromb. Haemost. 10(3), 437–446 (2012).
40. Yuana, Y., Bertina, R. M. & Osanto, S. Pre-analytical and analytical issues in the analysis of blood microparticles. Thromb. Haemost. 105(3), 396–408 (2011).
41. Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 105(30), 10513–10518 (2008).
42. Souza, M. F. D. et al. Circulating mRNA signature as a marker for high-risk prostate cancer. Carcinogenesis 105, 10513–10518 (2019).
43. Xue, V. et al. Non-invasive potential circulating mRNA markers for colorectal adenoma using targeted sequencing. Sci. Rep. 9(1), 12943 (2019).
44. Andaloussi, S. E. et al. Extracellular vesicles: Biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 12(5), 347–357 (2013).
45. Zaporozhchenko, I. A. et al. The potential of circulating cell-free RNA as a cancer biomarker: Challenges and opportunities. Expert Rev. Med. Diagn. 18(2), 133–145 (2018).
46. Baranayi, T. et al. Isolation of exosomes from blood plasma: Qualitative and quantitative comparison of ultracentrifugation and size exclusion chromatography methods. PLoS ONE 10(12), e0145686 (2015).
47. Coumans, F. A. et al. Methodological guidelines to study extracellular vesicles. Circ. Res. 120(10), 1632–1648 (2017).
48. Welsh, J. A. et al. MiFIoW-Cyt-EV: A framework for standardized reporting of extracellular vesicle flow cytometry experiments. J. Extracell. Vesicles 9(1), 1713526 (2020).
49. Yuana, Y. et al. Handling and storage of human body fluids for analysis of extracellular vesicles. J. Extracell. Vesicles 4, 29260–29260 (2015).
50. György, B. et al. Improved circulating microparticle analysis in acid-citrate dextrose (ACD) anticoagulant tube. Thromb. Res. 133(2), 285–292 (2014).
51. Palvainen, M. et al. Extracellular vesicles from human plasma and serum are carriers of extravesicular cargo—Implications for biomarker discovery. PLoS ONE 15(8), e0236439 (2020).
52. Shah, M. D. et al. Flow cytometric measurement of microparticles: Pitfalls and protocol modifications. Platelets 19(5), 365–372 (2008).
53. van Eijndhoven, M. A. et al. Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients. JCI Insight 1(19), e89631 (2016).
54. Ostenfeld, M. S. et al. miRNA profiling of circulating EpCAM+ extracellular vesicles: Promising biomarkers of colorectal cancer. J. Extracell. Vesicles 5(1), 31488 (2016).
55. Bode, A. P. et al. Vesiculation of platelets during in vitro aging. Blood 77(4), 887–895 (1991).
56. Thompson, C. B. et al. Size dependent platelet subpopulations: Relationship of platelet volume to ultrastructure, enzymatic activity, and function. Br. J. Haematol. 50(3), 509–519 (1982).

Acknowledgements
The authors would like to acknowledge Joshua A. Welsh from National Cancer Institute at NIH for helpful discussion and implementation of FCMap software. We are also grateful to Nick Wang of OHSU for facilitating access to Quantstudio 7 Flex Real-Time PCR systems. We are also grateful to Jeong Youn Lim for biostatistics advice and the Cancer Early Detection Advanced Research (CEDAR) center of the OHSU Knight Cancer Institute for assistance with obtaining blood samples. The authors also thank Pamela S Canaday, Brianna Garcia, and Dorian Latocha for flow cytometry training at Oregon Health and Science University. We acknowledge funding support from Cancer Early Detection Advanced Research (CEDAR) center at Oregon Health and Science University’s Knight Cancer Institute, Cancer Research UK/OHSU Project Award (C63763/A27122) and by grants from Kuni Foundation, Susan G. Komen Foundation (CCR21663959), the Department of Defense (W81XWH2110853), and the National Institutes of Health (R01HL101972, R21HD16-037, R01GM116184 and R01HL047014).

Author contributions
T.T.M.N. conceived and supervised the project. H.K., F.C., S.T.Y., and T.T.M.N. developed the initial workflow and established the blood processing optimization on EVs, platelets and cf-mRNA. T.K.M. and M.M. developed the flow cytometry assay in our group. H.K., M.J.R., F.C., T.K.M. and T.T.M.N. developed the analysis strategy. H.K., M.R., S.T.Y., R.A., F.C., and T.T.M.N. acquired and performed data analysis. H.K. and T.T.M.N. wrote the manuscript. T.K.M., M.J.R., S.T.Y., F.C., R.A., A.T.P.N., and O.J.T.M. edited the manuscript. All authors have reviewed and approved the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-06088-9.

Correspondence and requests for materials should be addressed to T.T.M.N.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022